Highly innovative and driven scientific executive and entrepreneur with the goal of positively impacting health care through new technology development.Kevin has over 20 years of experience in developing scalable assay technologies, and has published over 50 articles in peer reviewed journals, and filed more than 30 patents and patent applications. His technical expertise spans the fields of molecular biology, nucleic acid enzymology, assay development, surface chemistry, nanopore technology, and microfabrication. While at Illumina, Kevin led the Advanced Research Group and created several scalable genomic technologies including Illumina’s first $1B dollar product line based on the Infinium assay and enabled massively-parallel array-based whole genome genotyping, DNA copy number, FFPE, and methylation analysis. His team also championed Next-Gen Sequencing, and helped create a number of scalable Next-Gen Sequencing (NGS) assays and technologies including target enrichment assays, amplicon enrichment, targeted methylation, synthetic long read technologies, single cell technologies based on combinatorially indexed nuclei sequencing, and HiSeqX patterned flow cell technology. These efforts helped Illumina grow from a fledgling start-up to the world’s leading provider of Genomics and NGS instruments and assays. Prior to Illumina, Kevin was a research scientist at Affymetrix, developing array-based hybridization by sequencing and genotyping technology. This effort was preceded by a postdoctoral research at Stanford University studying the electrophysiology of the cystic fibrosis transmembrane regulator (CFTR) ion channel. Kevin holds a PhD in biophysics and MS in physics from Stanford University, and a B.A. in math/physics from St. Olaf College. Specialties: Design of genomics assays: genotyping, methylation, expression and sequencing. Assay development and optimization. DNA arrays, hybridization, enzymology, amplification. Science project management.